Metabolic disorders affecting the liver and heart: Therapeutic efficacy of miRNA-based therapies?

• DOI: 10.1016/j.phrs.2024.107083
• Publication Date: 2024-02-02T00:51:27Z
• Authors: Lucia La Sala; Valentina Carlini; Caterina Conte; Maria Belen Macas...; Elham Afzalpour; Jimmy Martin-Delgado; Marco D’Anzeo; Roberto F.E. Pedr...; Angelo Naselli; Antonio E. Pontiroli; Riccardo Cappato
• Keywords: Druggability

Liver and heart disease are major causes of death worldwide. It is known that metabolic alteration causing type 2 diabetes (T2D) Nonalcoholic fatty liver (NAFLD) coupled with a derangement in lipid homeostasis, may exacerbate hepatic cardiovascular diseases. Some pharmacological treatments can mitigate organ dysfunctions but the important side effects limit their efficacy leading often to deterioration tissues. needs develop new personalized treatment approaches recent progresses engineered RNA molecules becoming increasingly viable as alternative treatments. This review outlines current use antisense oligonucleotides (ASOs), interference (RNAi) genome editing for rare disorders. However, potential small non-coding RNAs serve therapeutic agents diseases yet be fully explored. Although miRNAs recognized biomarkers many diseases, they also capable serving drugs medical intervention; several clinical trials testing therapeutics diabetes, nonalcoholic well cardiac Recent advances RNA-based potentially facilitate novel application druggable targets. In this work, we sought summarize advancement advantages miRNA selective therapy when compared conventional drugs. particular, emphasise miRNAs, over ASOs or other Finally, address research questions related efficacy, side-effects, range therapeutics. Additionally, covered hurdles examined miRNA-based disorders such liver,